title: Overlap and discrepancy between tests for anti-C100, anti-GOR and anti-CP9 in patients with chronic liver disease and inhabitants in Saga, Japan.
abstract: The authors evaluated the clinical significance of anti-C100, anti-GOR and anti-CP9 in hepatitis C virus (HCV)-related liver disease in two populations: 459 healthy subjects and 385 patients with chronic liver disease (CLD). Previously we reported high rates of mortality and morbidity (5.3%) of CLD in subjects in Saga, Japan. This was ascribed to the high prevalence (10.8%) of anti-HCV among randomized populations, as detected by the C100 ELISA test system, as compared with a finding of 2-3% in Japanese blood donors in the same decade. The incidence of anti-C100, anti-GOR and anti-CP9 detected by ELISA test system in the healthy population currently surveyed was 17.0%, 19.2% and 32.0% respectively, as compared with 75.3%, 60.3% and 73.0% respectively, in those with CLD. The incidence of positivity for at least one of the three antibodies was high (36.4%) among healthy subjects, and even higher (86.5%) among the patients with CLD. In the healthy subjects, incidence of positivity increased with age. The healthy and CLD populations differed in the proportion of cases positive for all three antibodies vs. those positive for at least one antibody: healthy subjects, 52/167, 31.1%, vs. CLD patients, 197/333, 59.2%; P less than 0.01. Among the anti-C100-positive healthy cases, these was a significantly high level of AST, ALT, ZTT and gamma GTP compared with negative cases, with or without anti-GOR and anti-CP9 (P less than 0.01-0.05). These observations suggest that the presence of anti-C100 may be related to the active state of HCV-related liver disease.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Internal Medicine, Saga Medical School, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Setoguchi
authors.forename: K
authors.initials: K
authors.lastname: Yamamoto
authors.forename: I
authors.initials: I
authors.lastname: Ozaki
authors.forename: I
authors.initials: I
authors.lastname: Wada
authors.forename: T
authors.initials: T
authors.lastname: Hara
authors.forename: N
authors.initials: N
authors.lastname: Fujio
authors.forename: T
authors.initials: T
authors.lastname: Mizuta
authors.forename: T
authors.initials: T
authors.lastname: Sakai
authors.forename: F
authors.initials: F
authors.lastname: Nagumo
authors.forename: J
authors.initials: J
authors.lastname: Tadano
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000956:Antigens, Viral; D002908:Chronic Disease; D005260:Female; D016174:Hepacivirus / Q000276:immunology*; D006508:Hepatitis Antibodies / Q000032:analysis*; D006526:Hepatitis C / Q000276:immunology*; D018937:Hepatitis C Antibodies; D006801:Humans; D007564:Japan; D008107:Liver Diseases / Q000276:immunology*; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D017361:Viral Nonstructural Proteins; D014764:Viral Proteins / Q000032:analysis
chemical_list: D000956:Antigens, Viral; C064544:C100 protein, hepatitis C virus; D006508:Hepatitis Antibodies; D018937:Hepatitis C Antibodies; D017361:Viral Nonstructural Proteins; D014764:Viral Proteins